|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM32A |
Gene summary for FAM32A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM32A | Gene ID | 26017 |
| Gene name | family with sequence similarity 32 member A | |
| Gene Alias | OTAG-12 | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A024R7I4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26017 | FAM32A | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.69e-03 | 1.40e-01 | 0.0155 |
| 26017 | FAM32A | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.49e-15 | 4.81e-01 | -0.1808 |
| 26017 | FAM32A | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.88e-10 | 4.12e-01 | -0.0811 |
| 26017 | FAM32A | HTA11_78_2000001011 | Human | Colorectum | AD | 1.28e-07 | 2.73e-01 | -0.1088 |
| 26017 | FAM32A | HTA11_347_2000001011 | Human | Colorectum | AD | 1.43e-21 | 4.44e-01 | -0.1954 |
| 26017 | FAM32A | HTA11_411_2000001011 | Human | Colorectum | SER | 7.33e-10 | 7.88e-01 | -0.2602 |
| 26017 | FAM32A | HTA11_2112_2000001011 | Human | Colorectum | SER | 9.35e-13 | 8.01e-01 | -0.2196 |
| 26017 | FAM32A | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.73e-07 | 3.11e-01 | -0.1207 |
| 26017 | FAM32A | HTA11_83_2000001011 | Human | Colorectum | SER | 1.52e-08 | 3.92e-01 | -0.1526 |
| 26017 | FAM32A | HTA11_696_2000001011 | Human | Colorectum | AD | 1.16e-19 | 3.96e-01 | -0.1464 |
| 26017 | FAM32A | HTA11_866_2000001011 | Human | Colorectum | AD | 6.86e-05 | 2.36e-01 | -0.1001 |
| 26017 | FAM32A | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.97e-20 | 5.77e-01 | -0.059 |
| 26017 | FAM32A | HTA11_2992_2000001011 | Human | Colorectum | SER | 7.65e-03 | 2.94e-01 | -0.1706 |
| 26017 | FAM32A | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.96e-03 | 2.83e-01 | -0.2061 |
| 26017 | FAM32A | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.67e-07 | 5.23e-01 | -0.1462 |
| 26017 | FAM32A | HTA11_546_2000001011 | Human | Colorectum | AD | 9.68e-03 | 2.36e-01 | -0.0842 |
| 26017 | FAM32A | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.79e-05 | 3.49e-01 | -0.0179 |
| 26017 | FAM32A | HTA11_866_3004761011 | Human | Colorectum | AD | 3.21e-12 | 3.52e-01 | 0.096 |
| 26017 | FAM32A | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.31e-04 | 3.50e-01 | 0.0446 |
| 26017 | FAM32A | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.21e-02 | 2.70e-01 | 0.0131 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM32A | SNV | Missense_Mutation | c.196N>C | p.Glu66Gln | p.E66Q | Q9Y421 | protein_coding | tolerated(0.32) | probably_damaging(0.987) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM32A | SNV | Missense_Mutation | novel | c.271N>A | p.Asp91Asn | p.D91N | Q9Y421 | protein_coding | tolerated(0.09) | benign(0.041) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM32A | SNV | Missense_Mutation | c.182N>T | p.Ala61Val | p.A61V | Q9Y421 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.38A>C | p.Lys13Thr | p.K13T | Q9Y421 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FAM32A | SNV | Missense_Mutation | c.138G>T | p.Lys46Asn | p.K46N | Q9Y421 | protein_coding | tolerated(0.27) | probably_damaging(0.911) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.121N>G | p.Met41Val | p.M41V | Q9Y421 | protein_coding | tolerated(0.48) | benign(0.028) | TCGA-WX-AA44-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PR |
| FAM32A | SNV | Missense_Mutation | c.332C>T | p.Thr111Met | p.T111M | Q9Y421 | protein_coding | deleterious(0.02) | benign(0.09) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM32A | SNV | Missense_Mutation | novel | c.305N>G | p.His102Arg | p.H102R | Q9Y421 | protein_coding | deleterious(0) | benign(0.029) | TCGA-VQ-A8E3-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |